Merck’s New Pneumococcal Vaccine Headed to Regulators in 2020

, , ,

Merck reported results from two more Phase III trials of the company’s 15-valent pneumococcal conjugate vaccine V114, with plans to apply for approval to regulatory agencies before the end of 2020, beginning with the U.S. Food and Drug Administration.

Read more
/by

Merck Makes Headway with V114 Vaccine Against Pneumococcal Disease

, , , , , ,

Merck reported positive results regarding the safety, tolerability and immunogenicity in two Phase III studies for V114, the company’s investigational 15-valent pneumococcal conjugate vaccine.

Read more
/by